Trevena Reports Second Quarter 2023 Results and Provides Business Update
We look forward to updating you as these developments occur.”
- We look forward to updating you as these developments occur.”
Two TRV045 proof-of-concept studies near completion, exploring the potential for use in epilepsy and pain. - New respiratory data from ~200 patient VOLITION real-world outcomes study using continuous respiratory monitoring expected 3Q 2023.
- For the second quarter of 2023, the Company reported net revenue of $3.0 million, and a net loss attributable to common stockholders of $8.0 million, or $0.69 per share, compared to $15.0 million, or $2.26 per share in the second quarter of 2022.
- This cash balance does not include a $15 million non-dilutive tranche from the R-Bridge Financing that the Company anticipates receiving in the third quarter of 2023.